Orders placed after 1pm EST or on weekends will be shipped the next business day to maintain lab schedules
Goud PT, Goud AP, Joshi N, Puscheck E, Diamond MP, Abu-Soud HM
Misuse is
As a consequence, SELECT has raised the evidence threshold that innovators must clear when targeting conditions such as hypertension, dyslipidaemia or heart failure, including the effect size they need to demonstrate to be clinically meaningful and patient relevant

Mechanistic Understanding Gaps Fundamental aspects of PT-141s mechanism remain incompletely characterized: Precise molecular pathways linking MC4R activation to behavioral changes undefined Relative contributions of different melanocortin receptor subtypes unclear Role of downstream neurotransmitter systems (dopamine, norepinephrine, serotonin) incompletely mapped Why effects on sexual desire persist beyond drug elimination half-life remains unexplained Individual variation in response not well predicted by current biomarkers Long-Term Safety and Efficacy Data Critical safety questions remain inadequately addressed: Chronic use effects beyond one year unstudied in controlled trials Long-term cardiovascular safety requires extended monitoring given transient blood pressure effects Persistent hyperpigmentation risk with frequent use not fully characterized Developmental and reproductive toxicity data limited Effects on fertility and pregnancy outcomes require further study The longest controlled trial duration was 52 weeks, leaving questions about multi-year safety unanswered

Estrogens and experimental ischemic stroke: a systematic review